|
Rigel says Pfizer returns asthma therapy rights
Reuters May 6 (Reuters) – Rigel Pharmaceuticals Inc said Pfizer Inc has returned the rights to Rigel's inhaled asthma therapy, following the world's biggest drugmaker's decision to exit research and development in the allergy and respiratory therapeutic area. … Rigel Assumes Development Responsibility for Inhaled Asthma Therapy Pfizer Hands Back Rigel Drug |
View full post on asthma – Google News